Merck Exercises Option on Personalized Cancer Vaccine With Moderna
October 12 2022 - 8:02AM
Dow Jones News
By Colin Kellaher
Moderna Inc. and Merck & Co. on Wednesday said Merck has
exercised its option to jointly develop and commercialize
mRNA-4157/V940, a personalized cancer vaccine.
Kenilworth, N.J., drugmaker Merck would pay Moderna $250 million
to exercise its option and would collaborate on development and
commercialization of the vaccine with the Cambridge, Mass.,
biotechnology company.
Merck and Moderna, which have been working together since 2016,
said they would share costs and any profits equally under the
worldwide collaboration.
Moderna is currently conducting a Phase 2 study of
mRNA-4157/V940 in combination with Merck's blockbuster cancer drug
Keytruda as an adjuvant treatment for patients with high-risk
melanoma. The companies said they are on track to report data from
the study by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 12, 2022 07:47 ET (11:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024